ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA: EMPIRIC ANTIMICROBIAL THERAPY AND EXTRACORPOREAL MEMBRANE OXYGENATION

Community-acquired pneumonia (CAP) is one of the most frequent lung pathology. In cases with bacterial CAP early adequate empiric antibacterial therapy improves outcomes. Inadequate empiric antibiotic therapy increases resistance of nosocomial pathogens and worsens outcomes. Situation is much more confused in cases with viral pneumonia, complicated with acute respiratory distress syndrome (ARDS), required extracorporeal membrane oxygenation. We are presenting a serial of cases with viral pneumonia and ARDS with description and discussion of tactics and strategy of antimicrobial therapy.

Gritsan A.I., Yaroshetskiy A.I., Vlasenko A.V., Gavrilin S.V., Gel’fand B.R., Zabolotskikh I.B., et al. Diagnosis and intensive therapy of acute respiratory distress syndrome. Clinical recommendations of FAR. Anesteziologiya i reanimatologiya. 2016; 62(1): 62-70. (in Russian)

Avdeev S.N., Beloborodov V.B., Belotserkovskiy B.Z., Galstyan G.M., Gel’fand B.R., Dekhnich A.V., et al. Nosocomial pneumonia in adults (National recommendations). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2009; 11(2): 100-42. (in Russian)

Chuchalin A.G., Sinopal’nikov A.I., Kozlov R.S., Avdeev S.N., Tyurin I.E., Rudnov V.A., et al. Clinical recommendations for the diagnosis, treatment and prevention of severe community-acquired pneumonia in adults. Consilium Medicum. 2015; 17(3): 8-37. (in Russian)

Moroz V.V., Golubev A.M. Classification of acute respiratory distress syndrome. Obshchaya reanimatologiya. 2007; 3(6): 7-9. (in Russian)

Kassil’ V.L., Zolotokrylina E.S. Acute respiratory distress syndrome in the light of modern concepts. Vestnik intensivnoy terapii. 2000; (4): 3-7. (in Russian)

Kassil’ V.L., Zolotokrylina E.S. Acute respiratory distress syndrome in the light of modern concepts (Part 2). Vestnik intensivnoy terapii. 2001; (1): 9-14. (in Russian)

Steel H.C., Cockeran R., Anderson R., Feldman C. Overview of Community-Acquired Pneumonia and the Role of Inflammatory Mechanisms in the Immunopathogenesis of Severe Pneumococcal Disease. Mediators Inflamm. 2013; 2013: 490346.

Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-54.

Armitage K., Woodhead M. New guidelines for the management of adult community-acquired pneumonia. Curr. Opin. Infect. Dis. 2007; 20(2): 170-6.

Cilloniz C., Ewig S., Polverino E., Marcos M.A., Esquinas C., Gabarrús A., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011; 66(4): 340-6.

File T.M., Bartlett J.G., Thorner A.R. Treatment of community-acquired pneumonia in adults who require hospitalization. UpToDate. Available at: https://www.uptodate.com/contents/treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization

Wunderink R.G., Waterer G.W. Clinical practice. Community-acquired pneumonia. N. Engl. J. Med. 2014; 370(6): 543-51.

Crotty P.C., Meyers S., Hampton N., Bledsoe S., Ritchie D.J., Buller R.S., et al. Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship. Crit. Care. 2015; 19: 404.

Gattinoni L. Ultra-protective ventilation and hypoxemia. Crit. Care. 2016; 20: 130.

Cilloniz C., Ewig S., Ferrer M., Polverino E., Gabarrús A., Puig de la Bellacasa J., et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit. Care. 2011; 15: 209.

Chillcott S., Sheridan P.S. ECCO2R an experimental approach to treating ARDS. Crit. Care Nurse. 1995; 15: 50-6.

De Roux A., Ewig S., Garcia E., Marcos M.A., Mensa J., Lode H., et al. Mixed community-acquired pneumonia in hospitalised patients. Eur. Respir. J. 2006; 27: 795-800.

Lutfiyya M.N., Henley E., Chang L.F., Reyburn, S.W. Diagnosis and Treatment of Community-Acquired Pneumonia. Am. Fam. Physician. 2006; 73(3): 442-50.

Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect Dis. 2007; 44(Suppl. 2): 27-72.

Willkinson M., Woodhead M.A. Guidelines for community-acquired pneumonia in the ICU. Curr. Opin. Crit. Care. 2004; 10: 59-64.

Yoneyama H., Katsumata R. Antibacterial resistance in bacteria and its future fornovel antibiotic development. Biosci. Biotechnol. Biochem. 2006; 70: 1060-75.

Martén-Loeches I., Sanchez-Corral A., Diaz E., Granada R.M., Zaragoza R., Villavicencio C., et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A (H1N1) virus. Chest. 2011; 139(3): 555-62.

Palacios G., Hornig M., Cisterna D., Savji N., Bussetti A.V., Kapoor V., et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One. 2009; 4(12): 8540.

Hodgson C.L., Hayes K., Everard K., Nichol A., Davies A.R., Bailey M.J., et al. Long-term quality of life in patients with acute respiratory distress syndrome requiring extracorporeal membrane oxygenation for refractory hypoxaemia. Crit. Care. 2012; 16(5): R202.

Divo M., Cote C., de Torres J.P., Casanova C., Marin J.M., Pinto-Plata V., et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186(2): 155-61.

Mortensen E.M., Restrepo M., Anzueto A., Pugh J. Effects of guidelineconcordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am. J. Med. 2004; 117(10): 726-31.

Watanabe A., Yates P.J., Murayama M., Soutome T., Furukawa H. Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study. Antivir. Ther. 2015; 20(4): 415-23.

Whale A.S., Bushell C.A., Grant P.R., Cowen S., Gutierrez-Aguirre I., O’Sullivan D.M., et al. Detection of Rare Drug Resistance Mutations by Digital PCR in a Human Influenza A Virus Model System and Clinical Samples. J. Clin. Microbiol. 2016; 54(2): 392-400.

Sun H., Xue J.L., Bailey E., Xu Y., Hu G., Baroch J., et al. A quantitative RT-PCR assay for rapid detection of Eurasian-lineage H10 subtype influenza A virus. Virol. Sin. 2016; 31(5): 444-7.

Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Hama R., Thompson M.J., et al. Neuraminidase inhibitors for preventing and treating influenza in adult and children (Review). Cochrane Database Syst. Rev. 2014; (4): CD008965.

Voiriot G., Visseaux B., Cohen J., Nguyen L.B., Neuville M., Morbieu C., et al. Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia. Crit. Care. 2016; 20(1): 375.

Pietsch U., Müller-Höcker C., Enzler-Tschudy A., Filipovic M. Severe ARDS in a critically ill influenza patient with invasive pulmonary aspergillosis. Intensive Care Med. 2016; 42(10): 1632-3.

Van Heuverswyn F., Karczmarczyk M., Schimmel H., Trapmann S., Emons H. Influence of primer & probe chemistry and amplification target on reverse transcription digital PCR quantification of viral RNA. Biomol. Detect. Quantif. 2016; 9: 20-8.

Dulay A.T., Buhimschi I.A., Zhao G., Bahtiyar M.O., Thung S.F., Cackovic M., et al. Compartmentalization of acute phase reactants Interleukin-6, C-Reactive Protein and Procalcitonin as biomarkers of intra-amniotic infection and chorioamnionitis. Cytokine. 2015; 76(2): 236-43.

Liu B., Yin Q., Chen Y.X., Zhao Y.Z., Li C.S. Role of Presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department. Respir. Med. 2014; 108(8): 1204-13.

Gallego M., Pomares X., Capilla S., Marcos M.A., Suárez D., Monsó E., et al. C-reactive protein in outpatients with acute exacerbation of COPD: its relationship with microbial etiology and severity. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 2633-40.

Henriquez K.M., Hayney M.S., Rakel D.P., Barrett B. Procalcitonin Levels in Acute Respiratory Infection. Viral Immunol. 2016; 29(2): 128-31.

Prina E., Ceccato A., Torres A. New aspects in the management of pneumonia. Crit. Care. 2016; 20(1): 267.

Nakamura S., Izumikawa K., Yanagihara K., Miyazaki Y., Mukae H., Kohno S. New therapeutic strategies for pulmonary infection: the potency of immune activation by macrolides and Toll-like receptor agonist. Jpn J. Antibiot. 2016; 69(2): 91-100. (in Japanese)

Phillips O.A., Sharaf L.H. Oxazolidinone antimicrobials: a patent review (2012-2015). Expert. Opin. Ther. Pat. 2016; 26(5): 591-605.

Crum-Cianflone N.F. Invasive Aspergillosis Associated With Severe Influenza Infections. Open. Forum Infect. Dis. 2016; 3(3): ofw171.

Swoboda-Kopeć E., Sikora M., Piskorska K., Gołaś M., Netsvyetayeva I., Przybyłowska D., et al. Diagnosis of Invasive Pulmonary Aspergillosis. Adv. Exp. Med. Biol. 2017; 944: 27-33.

Bernal-Martínez L., Alastruey-Izquierdo A., Cuenca-Estrella M. Diagnostics and susceptibility testing in Aspergillus. Future Microbiol. 2016; 11(2): 315-28.

Leonardelli F., Macedo D., Dudiuk C., Cabeza M.S., Gamarra S., Garcia-Effron G., et al. Aspergillus fumigatus Intrinsic Fluconazole Resistance Is Due to the Naturally Occurring T301I Substitution in Cyp51Ap. Antimicrob. Agents Chemother. 2016; 60(9): 5420-6.

Siqueira J.P., Sutton D.A., García D., Gené J., Thomson P., Wiederhold N., et al. Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility. Fungal. Biol. 2016; 120(11): 1458-67.

Li H., Huang H., He H. Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review. BMC Pulm. Med. 2016; 16(1): 144.

Chang Y.T., Lin C.Y., Chen Y.H., Hsueh P.R. Update on infections caused by Stenotrophomonas maltophilia with particular attention toresistance mechanisms and therapeutic options. Front. Microbiol. 2015; 6: 893.

Hand E., Davis H., Kim T., Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J. Antimicrob. Chemother. 2016; 71(4): 1071-5.

Curbelo J., Galván J.M., Aspa J. Updates on Aspergillus, Pneumocystis and other opportunistic pulmonary mycoses. Arch. Bronconeumol. 2015; 51(12): 647-53.

Burk M., El-Kersh K., Saad M., Wiemken T., Ramirez J., Cavallazzi R. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur. Respir. Rev. 2016; 25(140): 178-88.

Cheng A., Sun H.Y., Tsai M.S., Ko W.J., Tsai P.R., Hu F.C., et al. Predictors of survival in adults undergoing extracorporeal membrane oxygenation with severe infections. J. Thorac. Cardiovasc. Surg. 2016; 152(6): 1526-36.

Lotz C., Roewer N., Muellenbach R.M. Respiratory and extracorporeal lung support. Anasthesiol. Intensivmed. Notfallmed. Schmerzther. 2016; 51(9): 574-81. (in German)

Papazian L., Herridge M., Combes A. Focus on veno-venous ECMO in adults with severe ARDS. Intensive Care Med. 2016; 42(11): 1655-7.